Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The topoisomerase I (Top 1) poison irinotecan is an important component of the modern treatment of colorectal cancer. By stabilising Top 1-DNA complexes, irinotecan generates Top 1-linked DNA single-strand breaks that can evolve into double-strand breaks and ultimately cause cell death. However, cancer cells may overcome cell killing by releasing the stalled topoisomerase from DNA termini, thereby reducing the efficacy of Top 1 poisons in clinics. Thus, understanding the DNA repair mechanisms involved in the repair of Top 1-mediated DNA damage provides a useful tool to identify potential biomarkers that predict response to this class of chemotherapy. Furthermore, targeting these pathways could enhance the therapeutic benefits of Top 1 poisons. In this review, we describe the cellular mechanisms and consequences of targeting Top 1 activity in cells. We summarise preclinical data and discuss the potential clinical utility of small-molecule inhibitors of the key proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“The efficacy of irinotecan in metastatic colorectal cancer was demonstrated in clinical trials conducted over a decade ago (Douillard et al, 2000; Saltz et al, 2000), with response rates to combination regimens of 30–50% and overall survival in some studies approaching 24 months (Fuchs et al, 2007).”
BackgroundRibic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 1×
“Mismatch repair-deficient colorectal cancers have been reported to be resistant to 5FU (Ribic et al, 2003), but more recent evidence indicates that they may be sensitive to irinotecan.”
BackgroundCalabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · cited 2×
“Cell line and xenograft data demonstrate the potentiating effect of PARP inhibition on the cytotoxicity of irinotecan (Miknyoczki et al, 2003; Calabrese et al, 2004; Smith et al, 2005).”
Background
Cited by
Karagöz, G. E., Acosta-Alvear, D., & Walter, P. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033886 · Cited by 310
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy
Ozturk, N., Ozturk, D., Kavakli, I. H., & Okyar, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102168 · Cited by 106
“Inhibition of this enzyme by irinotecan results in the DNA breaks and apoptosis [163].”
BackgroundDulong, S., Ballesta, A., Okyar, A., & Lévi, F. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0129 · Cited by 68
Meisenberg, C., Ashour, M. E., El-Shafie, L., Liao, C., Hodgson, A., Pilborough, A., Khurram, S. A., Downs, J. A., Ward, S. E., & El-Khamisy, S. F. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1026 · Cited by 59
Self-citationTargeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Wu, Y., Wang, K.-Y., Li, Z., Liu, Y.-P., Izumi, H., Uramoto, H., Nakayama, Y., Ito, K.-I., & Kohno, K. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-014-0112-7 · Cited by 17
“First, resistance to CPT seems to be partly caused by low TOPO1 activity [13,14,48], a finding that is consistent with our own YB-1 depletion experiments.”
BackgroundResult
Metadata
- Authors
- Gilbert, D. C., Chalmers, A. J., & El-Khamisy, S. F.
- Venue
- British Journal of Cancer
- Published
- 2011-11-22
- Volume
- 106
- Issue
- 1
- Pages
- 18-24
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2048342842
- Cited by
- 118
- References
- 3
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.